Immutep Limited (YP1A) - Total Liabilities
Based on the latest financial reports, Immutep Limited (YP1A) has total liabilities worth €48.30 Million EUR (≈ $56.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Immutep Limited to evaluate the company's liquid asset resilience ratio.
Immutep Limited - Total Liabilities Trend (2017–2024)
This chart illustrates how Immutep Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Immutep Limited.
Immutep Limited Competitors by Total Liabilities
The table below lists competitors of Immutep Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Generation Essentials Group
NYSE:TGE
|
USA | $6.81 Million |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
China | CN¥5.71 Billion |
|
Havanna Holding SA
BA:HAVA
|
Argentina | AR$74.01 Billion |
|
Donaco International Ltd
AU:DNA
|
Australia | AU$45.17 Million |
|
Orge Enerji Elektrik Taahhut AS
IS:ORGE
|
Turkey | TL1.77 Billion |
|
VerticalScope Holdings Inc
TO:FORA
|
Canada | CA$57.53 Million |
|
WinVest Acquisition Corp
NASDAQ:WINV
|
USA | $10.03 Million |
|
Korea Computer Inc
KQ:054040
|
Korea | ₩133.32 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Immutep Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Immutep Limited's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immutep Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immutep Limited (2017–2024)
The table below shows the annual total liabilities of Immutep Limited from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €12.06 Million ≈ $14.10 Million |
+9.82% |
| 2023-06-30 | €10.98 Million ≈ $12.84 Million |
-6.66% |
| 2022-06-30 | €11.76 Million ≈ $13.75 Million |
+34.30% |
| 2021-06-30 | €8.76 Million ≈ $10.24 Million |
-34.13% |
| 2020-06-30 | €13.30 Million ≈ $15.55 Million |
-17.68% |
| 2019-06-30 | €16.15 Million ≈ $18.89 Million |
+19.86% |
| 2018-06-30 | €13.48 Million ≈ $15.76 Million |
+59.84% |
| 2017-06-30 | €8.43 Million ≈ $9.86 Million |
-- |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more